Yokohama, Japan - March 5, 2025 - Alfresa Holdings Corporation (Headquarters: Chiyoda-ku, Tokyo) and Minaris Regenerative Medicine Co., Ltd. (Headquarters: Yokohama, Kanagawa are pleased to announce the signing of a Memorandum of Understanding (MoU) aimed at collaborating on Cell Therapy Development and Manufacturing for customers with the goal of enabling clinical and commercial manufacturing of cell therapy products in Japan.
Minaris is a leading global Contract Development and Manufacturing Organization (CDMO) specializing in Cell Therapy and regenerative medicine products. For over 25 years, we have provided our clients with expertise and technology through clinical and commercial manufacturing and process development. Minaris Group’s manufacturing facilities are located in the United States, Germany, and Japan, contributing to the rapid delivery of products to patients suffering from diseases worldwide.
The Alfresa Group supports Japan’s pharmaceutical supply chain, a crucial part of the country’s social infrastructure, through its various business domains, including the manufacturing and wholesale of pharmaceuticals and the operation of dispensing pharmacies. In response to diverse medical needs, the group works as a unified entity. As part of their new business initiatives, Cell Resources Co., Ltd. (hereinafter referred to as “Cell Resources”) is committed to building a “regenerative medicine supply chain.” Cell Resources, which engages in cell therapy and regenerative medicine-related businesses, is advancing the establishment of a comprehensive CDMO service system. This includes the provision of domestically procured cell sources, the manufacturing of cell-processed products, and partnerships with domestic and international alliance partners.
With the signing of this MoU, we will complement each other’s development and manufacturing capabilities through personnel exchanges and the joint use of various equipment and facilities owned by both companies. Additionally, cell procurement from Cell Resources will become possible. Furthermore, we will be able to propose a combined offering to domestic and international customers by leveraging Alfresa Holdings’ capabilities in manufacturing, storage, and transportation of regenerative medicine products, along with Minaris’ extensive contract manufacturing and process development expertise. By utilizing each company’s strengths, Minaris and Cell Resources will handle development and manufacturing, while the Alfresa Group will manage distribution, enabling us to undertake the entire process from early and late phase development and manufacturing to distribution.
Moving forward, Alfresa Holdings and Minaris will continue to strengthen their collaboration to contribute to the advancement of Cell Therapies and regenerative medicine.
For more information about Alfresa Holdings, please visit https://www.alfresa.com/eng/
For more information about Minaris, please visit https://www.rm.minaris.com/en/
Media Contact:
Midori Miyake
Business Development Department